BRONCHIOLITIS. This October, the health authorities warned of the return of bronchiolitis in children under two years old. 12 metropolitan regions are already in the epidemic phase.
[Mis à jour le 21 octobre 2022 à 17h15] In this second half of October, France is facing an epidemic of bronchiolitis. Thus, in his last stage, published on Wednesday, October 19, 2022, Public Health France reported that there is a continued increase in bronchiolitis surveillance indicators in children under 2 years of age. In this sense, SPF notes a 50% increase in emergency room visits for patients with bronchiolitis. Eight new regions (Auvergne-Rhône-Alpes, Bourgogne-Franche-Comté, Bretagne, Centre-Val de Loire, Grand Est, Guyana, Normandy and Pays de la Loire) entered the epidemic phase, bringing the total number of regions to 12 in a city.
Bronchiolitis is a highly contagious respiratory disease that mainly affects babies and the elderly is most often transmitted by adults and older children who are carriers of the virus without any symptoms or a simple cold. The epidemic spreads quickly because many people carry the virus and are contagious without knowing it. This seasonal disease usually begins in mid-October, peaks in December, and ends in late winter.
The Ile-de-France Regional Health Agency believes that the main problem encountered by health services is that the epidemic “coincides with a difficult context generated by tensions on human resources in health which impacts the capacity available within health establishments”. This is why “to date, 14 transfers in pediatric intensive care have been carried out to other regions, oriented in particular towards Amiens and Rouen”, specifies the ARS withParis news.
The infection initially resembles a cold or nasopharyngitis, accompanied by a slight fever. Quickly, a dry cough is added to these symptoms and the baby’s breathing is rapid and wheezy. If he is less than 6 months old, if he drinks only half of his bottles three times in a row, if he is a former premature baby aged less than three months, if he already has a respiratory disease or cardiac identified, if he vomits systematically, if he sleeps constantly or if he cries in an unusual way and cannot fall asleep, the child must be taken to the emergency room quickly. Generally, the symptoms subside in a few days and, in eight to ten days, the infant is cured – a residual cough can however persist for a fortnight, before disappearing.
In order to support healing, parents are advised to clean their child’s nose at least six times a day with physiological serum, in particular before giving him food or drink. It is also recommended to give him water regularly, in order to avoid any dehydration. Finally, splitting meals into smaller but more regular amounts aids healing. Physiotherapy sessions are sometimes also recommended to help patients breathe.
Bronchiolitis is a respiratory infection of the bronchioles (small bronchi located at the end of the bronchi), of viral origin, which affects babies. Common and highly contagious, it usually affects around 30% of babies under two years of age each year. It is the leading cause of pediatric hospitalization in children under two years of age. Causing a cough is labored, rapid, wheezing breathing, it is – most of the time – benign, although distressing for new parents. In some cases, it requires a visit to the emergency room, or even hospitalization. As a reminder, there is currently no vaccine against bronchiolitis: only its symptoms can be treated. Usually, it puts pressure on pediatric emergency services in mid-November, reaching its peak in December and ending at the end of winter.
It is recommended to limit visits to the circle of very close, non-sick adults. As far as possible, it is best not to take public transport, not to go to the supermarket or restaurant with babies under two months old, and to avoid large parties and family meals. We just have to keep these children safe from viruses, until they are strong enough to be able to resist them. It is really the first two months of life that lead children to serious forms of the disease.
If the child is infected, it is recommended, as far as possible, to find an alternative to the emergency room, not to go there directly, except for toddlers, those under two months old. The emergencies being overloaded, the other children, in particular when the symptoms are of low severity, must be taken care of by their general practitioner or their pediatrician. In the event of the appearance of the first symptoms of bronchiolitis, only children under two months old must absolutely consult the emergency room, where they will be hospitalized “a few hours or a few days for monitoring and treatment of symptoms”, specifies the French Society of Pediatrics on his website. The National Public Health Agency has given several recommendations to avoid contamination:
- By washing hands for 30 seconds with soap and water before or after contact with the infant.
- Avoid confined public places.
- Wash children’s toys.
- Ventilate the room where the baby sleeps at least 10 minutes a day.
- If an adult is sick around the child, do not kiss the baby and wear a mask.
The hope of a vaccine for 2023?
On Friday September 16, 2022, Sanofi announced in a communicated that a first vaccine against bronchiolitis, named Beyfortus, has been recommended by the European Medicines Agency, for all babies under the age of one. This vaccine developed jointly by Sanofi and AstraZeneca would be administered in a single dose. “If approved, Beyfortus will become the first and only single-dose passive immunizing agent indicated for all infants, including those who are healthy, born at term or prematurely, or those with certain medical conditions.” added the French company.
France info explains how this future protection will work: “Rather than a vaccine, Sanofi-AstraZeneca’s injectable solution is a preventive treatment, a monoclonal antibody that will protect babies under one year old throughout the epidemic period, it is i.e. fall and winter.” This preventive vaccine, which only concerns babies, excluding the elderly, should arrive in 2023 at the earliest, the time that the European Commission validates its marketing authorization.